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Abstract: Development of new medicines has become increasingly difficult with less possibility of success in 
seeds-finding and ever rising operational costs. Failure to comply with ethical standards for human research protection 
also erodes social trust in clinical development. In order to develop competence of professionals in medicines deve- 
lopment such as clinical investigators and drug development scientists, a variety of educational courses and training 
programs have been developed and executed worldwide. As Japan is no exception and shares the same concerns, sig-
nificant governmental and non-governmental efforts have been made to invest in the development of academic educa-
tional courses and adherence to international standards. This article introduces examples of the adoption of technologies 
to realize a user-friendly and sustainable learning management as well as an adaptation of syllabuses and core curricula 
to meet international standards in the era of global medicines development. 
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1. Introduction 
he discovery and development, regulation, and 
market introduction of medicines have become 
increasingly complex. Getting a new drug to 
market currently takes 13–15 years but the annual 
number of approved New Drug Applications has re-
mained flat at around 20 per year for the past 30 
years
[1]
. In addition, the costs to develop a new drug 
are increasing between US$ 2–3 billions on average
[2]
. 
Consequently, the efficiency of research and devel-
opment of new drugs in the US halves every nine 
years and declines as described by ―Eroom’s law‖
[3]
. A  
notable change is the industry’s recent interest in niche 
markets such as the development of orphan drugs  
often priced high, in which conventional development 
methodology cannot be applicable due to limited 
numbers of patients available for clinical evaluation of 
safety and efficacy of the product in question. To  
address the efficient medicine development under the 
current situation there is the growing need for profes-
sionals to understand the integrated process of deve- 
lopment, and manage all aspects of medicine deve- 
lopment with knowledge and competency of pharma-
ceutical medicine which could interface various as-
pects of the process. 
The International Federation of Associations of 
T 
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Pharmaceutical Physicians and Pharmaceutical Medi-
cine (IFAPP), a non-profit professional organization, 
has been promoting pharmaceutical medicine and 
medicines development by creating awareness and 
fostering education and training
[4,5]
. IFAPP also ex-
tended its partnership to develop PharmaTrain, one of 
the Innovative Medicines Initiative (IMI) educational 
projects, jointly undertaken between the European Co-
mmission and the European Federation of Pharmaceu-
tical Industries and Associations (EFPIA)
[6]
. Pharma-
Train provides standards and quality through a com-
mon syllabus and learning outcomes to form the cur-
riculum with modular structure. Moreover, Pharma-
Train has started the global implementation of its Ed-
ucation and Training system from 2014 to utilize the 
Shared Standards established in the EU for affiliates 
outside the EU.  
As a member country of the International Confer-
ence on Harmonization (ICH), Japan has experienced 
similar difficulties and decided to enhance its educa-
tional investment. Since the enforcement of ICH-GCP 
in 1997, the number of investigational new drug ap-
plications has significantly dropped in Japan
[7]
. The 
Japanese government, the Ministry of Health, Labor 
and Welfare (MHLW) and the Ministry of Education, 
Culture, Sports, Science and Technology (MEXT) 
started the ―Clinical trial activation plan‖ in 2003, a 
plan which has been revised three times since its initi-
ation. The latest 5-year plan was published in 2012
[8]
, 
in which, ―human resource development for clinical 
research‖ is the key topic. Japan has also taken the 
step to develop international partnerships in establish-
ing educational programs, such as the e-learning pro-
gram by the University of Tokyo in addition to educa-
tional activities by the Japanese Association of Phar-
maceutical Medicine (JAPhMed) which are based on 
PharmaTrain standards. 
2. Human resource development for clinical 
researchers in the University of Tokyo 
2.1 UMIN e-Learning  
UMIN e-Learning was developed on the ―University 
Hospital Medical Information Network (UMIN)‖. The 
UMIN was established in 1989 as a cooperative or-
ganization for national medical schools in Japan, 
sponsored by the MEXT. It is the largest and most 
versatile academic network information center for bi-
omedical sciences in the world, and is considered as 




A user with a UMIN account is eligible for e-lear-
ning. Because UMIN offers a single sign-on system, a 
potential user who doesn’t have an account can obtain 
one by simply accessing the web site (https://m-
oodle2.umin.ac.jp/moodle/), and follow the instruc-
tions to create a user account. 
The major feature of this e-learning is the systema-
tized program. The contents are stratified by profes-
sionals and skill-levels. The professionals have 6 cat-
egories: ―Medical doctor (MD)‖, ―Clinical research 
coordinator (CRC)‖, ―Institutional Review Board 
(IRB) member‖, ―Biostatistician (Biostat)‖, ―Medical 
clerk‖ and ―Data manager (DM)‖. The skill-levels 
have two categories: basic and advanced course. There 
are three types of courses for each level and profes-
sional: required (Req), optional (Opt), and not re-
quired (-). If a user completes all required courses, a 
certificate can be downloaded. 
Table 1 lists the basic courses which consist of 4 
sections and 32 items. Table 2 shows 13 items for the 
advanced course, most of which are in Japanese alt-
hough some are in English considering globalization 
and standardization measures. Some contents are for 
advanced focus on Clinical Data Interchange Standard 
Consortium (CDISC)
[10]
. As of October 2016, the Jap-
anese Pharmaceuticals and Medical Devices Agency 
(PMDA)
[11]
 has started to accept new drug applica-
tions in the form of the CDISC standards, thereby ur-
gently necessitating CDISC standards learning.  
The learning management system (LMS) is ―Moo-
dle‖, a free and open-source software
[12]
. Due to UMIN 
security policy, no customization has been applied for 
Moodle. Any customization would require continuous 
updates, which in turn would make it difficult to apply 
security patches distributed by the software’s producer. 
In addition, customization would be expensive. Con-
sequently, the user interface of this e-learning system 
is easy to maintain, and, as shown in Figure 1, quite 
simple. On the other hand, a user interface is im-
portant to attract additional users.  
2.2 Developing Syllabus for clinical education and 
new learning management system adjusted for new 
ethic guidelines 
Conducting clinical research requires expertise in 
safety, knowledge of data management and statistics, 
in addition to ethical considerations. The Ethical 
Guidelines for Medical and Health Research Involving 
Human Subjects enacted in April 2015
[13]
 put more  
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Table 1. Systematized program (Basic course part 1) 
Sec Contents MD CRC IRB Biostat Clerk DM 
Ⅰ Overview of clinical research Opt Req Opt Req Opt Req 
Basics of new drug development Opt Req Opt Req Opt Req 
Clinical research ethics Req Req Opt Req Opt Opt 
Legal requirements and guidelines Req Req Req Req Req Req 
Laws to protect personal information Req Req Req Req Req Req 
Compensation of clinical trials Req Req Req Opt Req Req 
Basic medical knowledge  Opt  Opt   
Diagnosis and treatment  Opt  Opt   
Clinical pharmacology  Req Opt Opt   
Diseases and medicine  Opt  Opt   
Biostatistics Req Req Opt Req  Req 
Life style-related diseases  Opt  Opt   
Ⅱ Elements necessary for clinical trial Req Req Opt Req Req Opt 
From the launch of trial to the application Opt Req Opt Opt Opt Opt 
Regulatory agency Req Req Req Opt Req Req 
Pharmaceutical industry  Req Opt Opt   
Medical institution Req Req Req Opt Req  
CRO & SMO Opt Req Opt Opt Req  
Roles & functions of medical institutions  Opt  Opt   
Ⅲ Understanding protocols Req Req Req Req Req  
How to read medical records  Opt  Opt   
How to read laboratory results  Req  Req  Req 
Data management Opt Req  Req  Req 
QC & QA Opt Req  Req Req Req 
MD: Medical doctor, CRC: Clinical research coordinator, IRB: Institutional Review Board member, Biostat: Biostatistician, Clerk: Medical clerk, 
DM: Data manager. Req: Requirement, Opt: Optional, : Unnecessary to learn. 
 
Table 2. Systematized program (Advanced course) 
Contents MD CRC IRB Biostat Clerk DM 
Global study Opt Opt Opt Opt Opt Opt 
1) Recent experience with ROCKET AF 
2) Registry study 
3) Database studies 
4) Biostatistics: Step up 
5) Strategy for clinical research 
Early & exploratory clinical development Req Req Opt Req Req Req 
Development of medical device Req Req Req Opt Opt Opt 
Consultation by PMDA Req Opt Req Req Opt Opt 
Medical writing Req Opt Opt Opt Req Opt 






MD: Medical doctor, CRC: Clinical research coordinator, IRB: Institutional Review Board member, Biostat: Biostatistician, Clerk: Medical clerk, 
DM: Data manager. Req: Requirement, Opt: Optional. 
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Figure 1. Screen shot of UMIN e-learning 
 
emphasis than ever on education and training for cli- 
nical researchers and others who will be involved in 
clinical research. According to the above guideline, 
―Investigators and other professionals shall receive 
education and training on the ethics of research and on 
knowledge and skills necessary to carry out the re-
search prior to its implementation. They shall also 
receive education and training during the research 
period on a regular basis as necessary.‖ 
However, due to the increased stringency and com-
plexity of regulations, clinical researchers are required 
to increase not only their knowledge of ethics, but also 
expertise on how to properly conduct research which 
includes methodological, regulatory, and organiza-
tional expertise. Occasionally this also includes proje-
ct management skills. It is common knowledge that 
those who work as physicians in hospital settings are 
already very busy, and have long – as well as irregular 
– working hours which in turn could result in exces-
sive workloads. Lack of appropriate skills could result 
in research misconduct, whereas those who are subject 
to compulsory education may suffer from an over-
whelm- ing workload. To ensure the quality and relia-
bility of the clinical research process, there is an ur-
gent need for continuous and systematic education of 
clinical research professionals once they have started 
to work in clinical settings. 
To adjust to the new requirements for clinical resea-
rchers, the University of Tokyo Hospital needed to re- 
consider and restructure compulsory education provid-
ed for its employees. Furthermore, it is necessary for 
some users to obtain a globally recognized certifica-
tion.  
Until 2015, the compulsory workload consisted of: 
1) Face-to-face compulsory ethics seminars on how to 
teach research ethics; 2) Compulsory within-hospital 
e-Learning on conflicts of interest and research integri-
ty; and 3) Face-to-face guidance for clinical research-
ers on protocol writing and informed consent writing.  
Our investigation concluded that points 2 and 3 
need to be kept given that 2 specifically explains rules 
at the University of Tokyo Hospital, and 3 was 
case-specific for each investigator, and subsequently 
could not be substituted by other alternatives.  
To develop a new educational system meeting glo-
bal standards, we have considered education syllabus-
es from all over the world aimed specifically at clinical 
investigators, and further investigated how we, as pro-
viders with scarce human resources, can best imple-
ment the developed syllabus for researchers with lim-
ited time.  
Through an extensive literature search
[14-16]
, we  
have found that PharmaTrain (an IMI programme on 
training in medicines development), and the European 
Clinical Research Infrastructures Network (ECRIN) 
joined force in 2011 to establish a European investi-
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gator training syllabus called CLIC (Clinical Investi-
gator Certification)
[17,18]
. CLIC is well structured and 
consists of 3 different levels of training related to dis-
tinct responsibilities in the performance of clinical 
trials, confirming that clinical investigators and inves-
tigative team members reach a similar level of com-
petency: Level 1: Site staff/sub-investigator, Level 2: 
Principal investigator/Site manager, and Level 3: 
Sponsor investigator.  
In order to follow the latest ethical guidelines and 
comply with requirements relevant for Japan, we have 
made some alterations to the CLIC syllabus. First, we 
have moved some ethics topics provided in Level 2 
into Level 1. Second, we have checked if we could 
cover compulsory content from the Collaborative In-
stitutional Training Initiative Japan Program
[19]
. Third, 
we have added and amended parts of the syllabus in 
order to cover the introduction of medical devices as 
well as regenerative medicine. These changes resulted 
in an increase from 10 to 12 chapters (Table 3). With 
regards to compulsory education, the University of 
Tokyo Hospital requires, as of July 2016, that princi-
pal investigators, sub-investigators and CRCs take all 
12 chapters, while research group members with other 
responsibilities are required to take between 1–3 chapters. 
2.3 CREDITS  
To include all the necessary requirements and needs 
stipulated by researchers, we have developed a con-
tinuous systematic education & training curriculum 
for clinical researchers and specialists entitled ―CRE-
DITS‖, Clinical Research EDucation and Interactive 
Training System (https://www.uhcta.com/uth/member/ 
index.cfm). 
 




1 History of clinical research and the subject's right 
2 Ethics and code of conduct of clinical research 
3 Ethics required to conduct clinical research 
4 Overview of development of medicine/ medical devices 
5 Introduction to clinical research methodology 
6 Legislative framework and guidance for clinical research 
7 Planning and preparation of a clinical study 
8 Site organization and management 
9 Subject recruitment, enrolment and retention 
10 Overview of in study procedures 
11 Introduction to safety 
12 Quality management system 
This is a life-long learning and training curriculum, 
aimed at nurturing clinical researchers and specialists, 
thereby ensuring continued development of research-
ers’ collective capabilities based on available and up- 
to-date global standards.  
CREDITS is a multiple learning system where us-
ers can, among other options, take ICT programs 
(e-learning and web seminars), and submit applica-
tions for participation in face-to-face seminars.  
Each user’s training log is recorded on the system, 
allowing the participants to keep track of their attend-
ance record. Reminders are sent prior to the expiration 
of each user’s validity period, thereby enabling them 
to continue with their learning. Moreover, the system 
encompasses knowledge of clinical research based on 
global standards which is useful when conducting 
global clinical trials.  
Cooperation between researchers and other profes-
sionals (such as CRC, biostatisticians, data managers, 
monitors, auditors and ethic committee members) is 
vital to ensure the reliability of clinical research. It is 
thus essential to build a baseline training curriculum 
for all professionals involved in research, irrespective 
of background and current position. 
2.4 Collaboration with other universities 
Based on the background above, The Clinical Re-
search Support Center of the University of Tokyo 
has been collaborating with two relevant working gro-
ups: 1) The National University Hospital Clinical Re-
search Initiative (NUH-CRPI), founded in October 
2012 to promote clinical studies and clinical research 
at national university hospitals by supporting prepara-
tion of systems for conducting high-quality clinical 
research and clinical studies safely and efficiently 
through information sharing and coordination, and 2) 
The University Hospital Clinical Trial (UHCT) Alli-
ance, a volunteer group consisting of 8 universities in 
the Kanto area established in Feb 2006 in collabora-
tion with industry associations, and funded by MEXT. 
Together with NUH-CRPI, the aforementioned syl-
labus is the product of the University of Tokyo’s posi-
tion as a central workforce of a topic group on setting 
the learning objectives for education and training and 
creating a syllabus for clinical researchers in Japan.  
As for the implementation of the new syllabus, to-
gether with the UHCT Alliance learning management 
system, we developed CREDITS to maximize the 
ability of each national university hospital (Figure 2). 
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Figure 2. Screen shot and main function of CREDITS 
 
So far, we are providing mandatory learning cou-
rses on ethics and on the topic of how to conduct clin-
ical research both prior to the approval of research 
plans as well as during ongoing research projects. 
CREDITS is a program which has just been recent-
ly introduced (October, 2016) with a gradual increase 
in e-learning content and the number of face-to-face 
seminars. We have thus not yet been able to assess the 
effectiveness of CREDITS. Potential evaluation indi-
cators will be based not only on the number of com-
pleted certification programs but on more substantial 
measures such as the amount of clinical research con-
ducted in the user universities, and fewer reports of 
research misconduct or an increased number of clini-
cal research articles which abide by current research 
guidelines. 
3. Educational activities in pharmaceutical 
medicine by JAPhMed 
JAPhMed was established in 1969 as a professional 
organization by physicians working in pharmaceutical 
industry, and it joined IFAPP in 1975 as its national 
member association in Japan. Under its vision and 
mission to promote pharmaceutical medicine,    
JAPhMed has actively committed to facilitate educa-
tional opportunities. 
As a local implementation of the global quality 
standards by PharmaTrain on Education and Training 
(E&T) of pharmaceutical medicine, JAPhMed took 
the first initiative by establishing the nation’s first 
pharmaceutical medicine course in collaboration with 
Osaka University, and recently started a second initia-
tive by implementing the pilot project of Specialist in 
Medicine Development (SMD) program which is the 
competency- and workplace-based education and cer-
tification in collaboration with ACRP-Japan and EF-
PIA-Japan.  
3.1 Pharmaceutical medicine educational course in 
Japan 
Utilizing governmental efforts to revitalize develop-
ment of pharmaceutical medicine in Japan from 1990s, 
Osaka University developed the Clinical Research 
Professional (CRP) training course program targeting 
postgraduate students and industry employees to teach 
fundamentals of the development of drugs and medi-
cal devices. This program is accredited as part of the 
curricula of the Graduate School of Osaka University. 
Taking advantage of this prior establishment at 
Osaka University, JAPhMed has started to collaborate 
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with Osaka University and undertaken to expand this 
program along with the PharmaTrain syllabus and 
curriculum to meet PharmaTrain quality standards. In 
2013, Osaka University started a two-years course in 
pharmaceutical medicine which is fully aligned with 
the PharmaTrain program.  
In particular, by selecting a number of suitable 
modules from the CRP training course, the new course 
was amended to meet PharmaTrain standards. Accord- 
ingly, some additional modules were added in 2013 to 
form a one-year ―Base Course‖ comprised of the 6 
PharmaTrain Base Course Modules. In 2014, this was 
followed by 4 Extension and 4 Elective Modules 
aligned with the ―Extension Master‖ curriculum con-
ditions of PharmaTrain. The Module composition of 
the Pharmaceutical medicine educational course in 
2014 is shown in Figure 3.  
This course is offered to the students at two sites, 
one is in the course organizer’s facilities in Osaka and 
the other is at Osaka University’s remote office in 
Tokyo, allowing the participation of students in Tokyo 
via videoconferencing attended by a local facilitator. 
Although this course is the first integrated educational 
program in pharmaceutical medicine in Japan, it is not 
possible to achieve a master’s degree from Osaka 
University due to governmental regulations. Instead, 
the university is certifying successful completion of 
the respective modules within this overall program by 
issuing the CRP Certificate. On the other hand,   
JAPhMed is issuing a ―Year 1-Certificate in Pharma-
ceutical Medicine‖ and a ―Year 2-Certificate in Phar-
maceutical Medicine‖.  
In April 2015, following an audit by PharmaTrain, 
this course was the first in Asia to be awarded a Cen-
tre of Excellence (CoE) recognition. 
3.2 Specialist in Medicine Development (SMD) 
program in Japan  
Under the changing and complex status of medicines 
development, academically qualified people in the 
workplace further pursue to obtain higher degrees and 
acquire a certain array of competencies across multi-
ple domains through their on-the-job training and 
university training courses. There is, however, cur-
rently no qualification/degree/title available which 
certifies such achievement.   
A Specialist in Medicine Development (SMD) title 
for pharmaceutical physicians and scientists based on 
the concept of competency-based and vocational train-
ing is developed to fill the above-mentioned gap
[20]
. In 
particular, a working group of representatives from 




Figure 3. The module composition of the pharmaceutical medicine educational course in 2014 
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office and national member associations is formed and 
expected to define core competencies for the SMD 
E&T system
[21]
. The core competencies for pharma-
ceutical physicians and drug development scientists 
were developed to align with the Learning Outcome of 
the PharmaTrain Base course. Thus, 7 domains and 57 
core competencies were identified and aligned ac-
cordingly. Each competency is evaluated by perspec-
tives of acquired knowledge, skills and attitudes/be-
haviors. The structure of these domains and compe-
tencies is shown in Figure 4 (modified from Appendix 
13.4 of the PharmaTrain Manual).   
A minimum of 2 of the 6 operational domains rele-
vant to the professional work in medicines develop-
ment, and one general domain for communication, 
management and leadership must be completed in the 
workplace to be awarded the SMD title. The frame-
works of the SMD program such as organization, 
management, administration and governance are de-
fined under the auspices of PharmaTrain
[1,6]. 
 
In accordance with the timing when we obtained 
the first graduates of the pharmaceutical medicine 
course at Osaka University, JAPhMED has developed 
the next and advanced E&T program. The concept of 
SMD advocated by PharmaTrain, and the qualifica-
tions assessed by outcomes through competency-ba-
sed and vocational training are well received by the 
academic graduates and also meet the needs of medi-
cines developing scientists initially educated in Japa-
nese pharmaceutical companies. JAPhMed is currently 
cooperating with ACRP-Japan and EFPIA-JAPAN and 
is, as of June 2016, undertaking the pilot program of 
SMD.  
Entry criteria for SMD candidates in the Japanese 
program are following the instructions by Pharma-
Train: A) Have completed a formal education (BSc, 
MSc, MD, PharmD, RN, DV, PhD or equivalent) in 
life science or healthcare e.g. medical doctors, phar-
macists, biologists, chemists, biometricians, certified 
nurses). B) Hold a function in Pharmaceutical Medi-
cine/ Medicines Development Science, or intend to 
hold such a function for the practical competen-
cy-based, workplace-centred training towards the 
SMD Award. C) Have a named and qualified mentor 
in the workplace (such as a line-manager), responsi-
ble for overseeing and facilitating their training. So 
far 10 candidates from pharmaceutical companies 
and academic clinical institutions are enrolled and 
preparing for the pilot implementation of the SMD 
program in Japan.  
 
 





C6. THE EVALUATION OF THE ADVANCES MADE IN THE 
CLINICAL PHARMACOLOGY OF A NEW MEDICINE IN A 
STEPWISE MANNER WITH THE RALL CDP & THE TTP. 
C7. EXPLANATION OF THE STATISTICAL PRINCIPLES FOR 
THE DESIGN, CONDUCT & ASSESSMENT OF 
EXPLORATORY STUDIES. 
C8. JUSTIFICATION FOR THE VARIOUS END-POINTS USED 
IN THE CLINICAL DEVELOPMENT PROGRAMME. 
C9. APPRAISAL OF SUSPECTED ADVERSE EVENTS 
DURING EXPLORATORY DEVELOPMENT. 
 
C5. THE DESIGN & EXECUTION OF EXPLORATORY STUDIES 
& EVALUATION OF THE RESULTING DATA AS APPLIED TO 
THE CLINICAL DEVELOPMENT PLAN. 
C4. CREATION OF A CLINICAL DEVELOPMENT PLAN 
(CDP) FOR A NEW CANDIDATE INCLUDING A TARGET 
PRODUCT PROFILE (TPP). 
C3. EVALUATION & APPLICATION OF THE REGULATORY & 
ETHICAL ASPECTS UNDERPINNING CLINICAL 
DEVELOPMENT. 
C2. EVALUATION OF THE CLINICAL & NON-CLINICAL 
PHARMACOLOGY & TOXICOLOGY EVIDENCE FOR A NEW 
CANDIDATE FOR CLINICAL DEVELOPMENT. 
C1. EVALUATION & ANALYSIS OF A DISEASE AREA WITHIN 
THE INDUSTRY CLINICAL DEVELOPMENT ENVIRONMENT 
& IDENTIFICATION OF UNMET THERAPEUTIC NEEDS. 
Akiko Kishi, Ichiro Uchida, Daisuke Koide, et al. 
 
 Journal of Medicines Development Sciences (2017)–Volume 3, Issue 1 9 
4. Conclusion 
In the evermore competitive global environment of 
medicines development, many issues can be shared 
internationally but solutions are unique to target 
groups, regions, and nations to meet different social 
cultures and infrastructures. 
Japan has established ―today’s status‖ among the 
many nations strong in medicines development, based 
on its intense national investment in academic educa-
tion in science and technology as well as vocational 
training in the workplace. Despite the rapidly chang-
ing environment and diversity in medicines develop-
ment involving medical devices and regenerative 
medicine, fundamental strength continues to come 
from the development of excellent human resource. 
Professional education and training meeting interna-
tional standards, and the needs of different learning 
styles will be required to survive the next generation. 
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